Evaluation of CPT-11 in combination with doxorubicin against pancreatic ductal adenocarcinoma PO3 on B6D2F1 female mice BCM-887 (10.30.96-02.27.97)

	Comments		live		4/5 ·— HDT highly active 0/5 Active 0/5 Active		ctive	ctive			
			Inactive	- HDT hig	Active	4/5 HDT highly active	Highly active	Highly active	Active	Inactive	
Turnor free	survivors day 120	0/5 - HDT active	9/0	4/5 1 1	9/2	4/5	1/5	9/0	9/0	9/2	0/10
log cell	kıllı	1.3	0.5	12	10		4.7	3.1	9.1	0.5	
<u>۲</u>	in days	9,8 9,3	4 0	9.5	7.5		35.6	23 5	12.3	4.1	
Time for median	tumor to reach 1000 mg in days	26.2 25.7	20.4	25.9	23.9		52.0	39,9	28.7	20.5	16.4
1/C	ctay 16	9 7	52	o 7 :	45	0	0	0	æ	37	
Median tumor	day 16 (range)	75 (0-126) 126 (32-340)	291 (0-1162)	126 (0-214)	362 (32-546)	(n-n) n	(0-0) 0	(0-0) 0	72 (0-126)	336 (270-942)	918 (343-1444)
Average body weight	at nadir (day of nadir)	-3.9 (13)	-3.3 (13)	-4.4 (13) -6.1 (15)	103 (13)	(61) 6:01-	-6.9 (13)	-2.5 (8)	-3.9 (13)	-1.8 (14)	
Drug death (days of	death)	0/5 0/5	0/5	0/5	0/5) ;	9/2	9/0	9/0	9/0	-
Fraction of HDT	-		1		0.5)	0.8) 1.3	0.41) 0.65) 1.06	0.31) 0.50) 0.81	0.22) 0.35).0.57	0.12)	,
Total	in mg/kg 806.4	500.0	20.0	12.4 7.6	10.0	644.8	8.2 524.0	6.2 403.2	4.4 282.4	2.4 160.8	
Schedule in days	6.9	(2v/day)	6'9		6,9	6-9	(Zv/day)				
Dosage in mg/kg/dose	100.8	62.5 38.8	10.0	6.2 3.8	5.0	90.0	4.1 65.5	3,1 50.4	2.2 35.3	1.2	
Route	p.o.	0.2 ml	!v.	0.2 ml	iv/0.2ml	po/0.2ml					
Agent (batch)	CPT-11		Doxorubicin		Doxorubicin	CPT-11					Control

Tumor doubling time ≈ 2.3 days. Mice average weight: CPT-11 = 24.39 g, doxorubicin = 25.26 g, combination = 23.50 g. The 2 administrations of CPT-11 were performed 4 hours apart.
Abbreviation used; HDT = highest dose tested.